Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menü

Klinische Studien von BMS suchen
BMS-Symbol für "Studie, für die rekrutiert wird"

Recruiting

Studien-Nr. CN012-0038  |   NCT06929273

A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

Zusammenfassung

  • Phase 3
  • Symbol für männliches und weibliches Geschlecht
  • 18-65
    Altersgruppe
  • 63
    Standorte
  • BMS-Symbol für "Studie, für die rekrutiert wird"
    Recruiting

Überblick

This is a phase 3, open-label extension study to assess the long-term safety of KarXT for the treatment of mania or mania with mixed features in Bipolar-I disorder (BP-I) The primary objective of the study is to evaluate the long-term safety and tolerability of KarXT in the treatment of participants with mania or mania with mixed features associated with BP-I.

Druckmedium-alt Druckmedium
email E-Mail

Nächstgelegenes Prüfzentrum

Wichtigste Einschlusskriterien

Einschlusskriterien

Symbol für Einschlusskriterien img
:
  • Participants who participated in double-blind placebo-controlled study (CN0120036 or CN0120037): a. Participants must have completed treatment period of parent study.
    1. De novo participants who did not participate in double-blind placebo-controlled studies: 1. Participants must have primary diagnosis of Bipolar-I disorder established by a comprehensive psychiatric evaluation based on DSM-5-TR criteria and confirmed by the Mini International Neuropsychiatric Interview (MINI, v7.0.2), with symptoms of mania or mixed mania. 2. Participants must have Young Mania Rating Scale (YMRS) score of ≥ 14 at Screening and at baseline. 3. Participants must have CGI-BP score of ≥ 3 at Screening and at baseline. 4. Participants does not require hospitalization for acute mania.

      Ausschlusskriterien

      Symbol für Ausschlusskriterien
      :
      • Participants who participated in double-blind placebo-controlled study (CN0120036 or CN0120037): a. Discontinuation from any KarXT parent studies.
        1. De novo participants who did not participate in double-blind placebo-controlled studies: 1. All participants with a risk for suicidal behavior at baseline as determined by Investigator's clinical assessment or history of suicidal behavior as assessed on C-SSRS. 2. Participants must not have primary diagnosis of BP-I with rapid cycling (ie, ≥ 4 distinct mood episodes in one year). 3. Participants must not have any primary DSM-5-TR disorder other than BP-I with mania or mania with mixed features within 12 months before Screening (confirmed using MINI version 7.0.2 at Screening), including BP-I with depression, (previous 3 months only), Bipolar-II disorder, major depressive disorder, and primary psychotic disorder, with the exception of mild anxiety disorders. 4. Individual has a DSM-5-TR diagnosis of moderate to severe substance use disorder (except tobacco use disorder) within the 12 months before Screening (confirmed using MINI version 7.0.2 at Screening), or current use as determined by urine toxicology screen or alcohol test. 5. Participants must not have history of irritable bowel syndrome (with or without constipation) or serious constipation requiring treatment within the last 6 months. 6. Participants must not have history or high risk of urinary retention, gastric retention, or untreated narrow-angle glaucoma. 7. Other protocol-defined Inclusion/Exclusion criteria apply.
          Zusätzliche Informationen*

          Behandlungsmöglichkeiten

          Studienarme

          ZUGEWIESENE BEHANDLUNG

          Studienarme

          Experimental: KarXT

          ZUGEWIESENE BEHANDLUNG
          • Drug: KarXT
          Prüfen Sie, ob eine der klinischen Studien für Sie infrage kommt
          Kommt die Studie für Sie infrage
          Beantworten Sie einige Fragen zu Ihrer Gesundheit, um festzustellen, ob diese Studie für Sie infrage kommt
          Geeignete Studie
          Wenn ihnen eine passende Studie angezeigt wird, klicken Sie auf die Studie, damit Sie die Liste der Prüfzentren angezeigt bekommen.
          Wählen Sie einen Prüfzentrumsstandort aus
          Wählen Sie einen Prüfzentrumsstandort aus, der für Sie günstig ist
          Registrieren
          Geben Sie Ihre Kontaktdaten ein, damit das Prüfzentrum mit Ihnen Kontakt aufnehmen kann.

          Unterstützen Sie uns dabei, Ihre Nutzung der Website zu optimieren! Teilen Sie Ihr Feedback mit unserem Team bei BMS Clinical Trials, um die Nutzung der Webseite, Ihre Erfahrungen und die anderer zu verbessern. Vielen Dank!